Trial Profile
Clinical study to evaluate the efficacy and safety of TA-650 in patients with psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2017
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 24 May 2016 New trial record